Amivantamab (Rybrevant, Johnson & Johnson) in combination with carboplatin and pemetrexed is indicated for 'the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor (EGFR) Exon 20 insertion mutations'.
The dosage schedule is available in the summary of product characteristics for amivantamab.
The list price for amivantamab is £1,079 per 350‑mg vial (excluding VAT; BNF online, accessed February 2025).
The company has a commercial arrangement. This makes amivantamab with carboplatin and pemetrexed available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, the Carbon Reduction Plan for UK carbon emissions is published on Johnson & Johnson's webpage on their responsibility to the planet.